Abdullah MI, Junit SM, Ng KL, Jayapalan JJ, Karikalan B, Hashim OH. Papillary Thyroid Cancer: Genetic Alterations and Molecular Biomarker Investigations. Int J Med Sci. 2019;16(3):450-60. https://doi.org/10.7150/ijms.29935.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nikiforov YE. RET/PTC rearrangement in thyroid tumors. Endocr Pathol. 2002;13(1):3-16. https://doi.org/10.1385/ep:13:1:03.

Article  CAS  PubMed  Google Scholar 

Cancer Genome Atlas Research N. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159(3):676–90. https://doi.org/10.1016/j.cell.2014.09.050.

Kheder ES, Hong DS. Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins. Clin Cancer Res. 2018;24(23):5807-14. https://doi.org/10.1158/1078-0432.CCR-18-1156.

Article  CAS  PubMed  Google Scholar 

Haddad R, Elisei R, Hoff AO, Liu Z, Pitoia F, Pruneri G, et al. Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid Carcinomas: A Review. JAMA Oncol. 2023;9(8):1132-41. https://doi.org/10.1001/jamaoncol.2023.1379.

Article  PubMed  Google Scholar 

Chu YH, Sadow PM. Kinase Fusion-Related Thyroid Carcinomas: Towards Predictive Models for Advanced Actionable Diagnostics. Endocr Pathol. 2022;33(4):421-35. https://doi.org/10.1007/s12022-022-09739-9.

Article  PubMed  PubMed Central  Google Scholar 

Mete O, Boucher A, Schrader KA, Abdel-Rahman O, Bahig H, Ho C, et al. Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer Management. Endocr Pathol. 2024;35(4):293-308. https://doi.org/10.1007/s12022-024-09836-x.

Article  PubMed  PubMed Central  Google Scholar 

Capdevila J, Awada A, Fuhrer-Sakel D, Leboulleux S, Pauwels P. Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era. Cancer Treat Rev. 2022;106:102380. https://doi.org/10.1016/j.ctrv.2022.102380.

Article  CAS  PubMed  Google Scholar 

Marchetti A, Ferro B, Pasciuto MP, Zampacorta C, Buttitta F, D'Angelo E. NTRK gene fusions in solid tumors: agnostic relevance, prevalence and diagnostic strategies. Pathologica. 2022;114(3):199-216. https://doi.org/10.32074/1591-951X-787.

Article  PubMed  PubMed Central  Google Scholar 

Pekova B, Sykorova V, Mastnikova K, Vaclavikova E, Moravcova J, Vlcek P, et al. NTRK Fusion Genes in Thyroid Carcinomas: Clinicopathological Characteristics and Their Impacts on Prognosis. Cancers (Basel). 2021;13(8). https://doi.org/10.3390/cancers13081932.

Slack JC, Hollowell M, Barletta JA. Thyroid Nodules and Follicular Cell-Derived Thyroid Carcinomas in Children. Endocr Pathol. 2023;34(2):165-75. https://doi.org/10.1007/s12022-023-09764-2.

Article  PubMed  Google Scholar 

Hechtman JF, Benayed R, Hyman DM, Drilon A, Zehir A, Frosina D, et al. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. Am J Surg Pathol. 2017;41(11):1547-51. https://doi.org/10.1097/PAS.0000000000000911.

Article  PubMed  PubMed Central  Google Scholar 

Marchio C, Scaltriti M, Ladanyi M, Iafrate AJ, Bibeau F, Dietel M, et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol. 2019;30(9):1417-27. https://doi.org/10.1093/annonc/mdz204.

Article  CAS  PubMed  Google Scholar 

Lee YC, Chen JY, Huang CJ, Chen HS, Yang AH, Hang JF. Detection of NTRK1/3 Rearrangements in Papillary Thyroid Carcinoma Using Immunohistochemistry, Fluorescent In Situ Hybridization, and Next-Generation Sequencing. Endocr Pathol. 2020;31(4):348-58. https://doi.org/10.1007/s12022-020-09648-9.

Article  CAS  PubMed  Google Scholar 

Kong Y, Bu R, Parvathareddy SK, Siraj AK, Siraj N, Al-Sobhi SS, et al. NTRK fusion analysis reveals enrichment in Middle Eastern BRAF wild-type PTC. Eur J Endocrinol. 2021;184(4):503-11. https://doi.org/10.1530/EJE-20-1345.

Article  CAS  PubMed  Google Scholar 

Lee SE, Lee MS, Bang H, Kim MY, Choi YL, Oh YL. NTRK Fusion in a Cohort of BRAF p. V600E Wild-Type Papillary Thyroid Carcinomas. Mod Pathol. 2023;36(8):100180. https://doi.org/10.1016/j.modpat.2023.100180.

Hechtman JF. NTRK insights: best practices for pathologists. Mod Pathol. 2022;35(3):298-305. https://doi.org/10.1038/s41379-021-00913-8.

Article  PubMed  Google Scholar 

Kim SY, Kim T, Kim K, Bae JS, Kim JS, Jung CK. Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in Koreans. J Pathol Transl Med. 2020;54(4):310-7. https://doi.org/10.4132/jptm.2020.05.12.

Article  PubMed  PubMed Central  Google Scholar 

Bankhead P, Loughrey MB, Fernandez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: Open source software for digital pathology image analysis. Sci Rep. 2017;7(1):16878. https://doi.org/10.1038/s41598-017-17204-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu YA, Aung PP, Wang Y, Ning J, Nagarajan P, Curry JL, et al. TRPS1 expression in non-melanocytic cutaneous neoplasms: an immunohistochemical analysis of 200 cases. J Pathol Transl Med. 2024;58(2):72-80. https://doi.org/10.4132/jptm.2024.01.23.

Article  PubMed  PubMed Central  Google Scholar 

Lee DH, Jeong IH, Jang B. Elevated expression of Axin2 in intestinal metaplasia and gastric cancers. J Pathol Transl Med. 2023;57(6):315-22. https://doi.org/10.4132/jptm.2023.10.12.

Article  PubMed  PubMed Central  Google Scholar 

Bae JS, Jung SH, Hirokawa M, Bychkov A, Miyauchi A, Lee S, et al. High Prevalence of DICER1 Mutations and Low Frequency of Gene Fusions in Pediatric Follicular-Patterned Tumors of the Thyroid. Endocr Pathol. 2021;32(3):336-46. https://doi.org/10.1007/s12022-021-09688-9.

Article  CAS  PubMed  Google Scholar 

Kim Y, Kim MH, Jeon S, Kim J, Kim C, Bae JS, et al. Prognostic implication of histological features associated with EHD2 expression in papillary thyroid carcinoma. PLoS One. 2017;12(3):e0174737. https://doi.org/10.1371/journal.pone.0174737.

Article  CAS  PubMed  PubMed Central  Google Scholar